{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:35:25Z","timestamp":1780410925145,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,8,24]],"date-time":"2013-08-24T00:00:00Z","timestamp":1377302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,8,24]],"date-time":"2013-08-24T00:00:00Z","timestamp":1377302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10637-013-0015-z","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T05:07:37Z","timestamp":1377234457000},"page":"1514-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"31","author":[{"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongtae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Seok","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon Seo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Ick","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,24]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926\u20131945","journal-title":"Genes Dev"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2174\/156652405774641034","volume":"5","author":"FJ Giles","year":"2005","unstructured":"Giles FJ, Albitar M (2005) Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5:653\u2013661","journal-title":"Curr Mol Med"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ijc.21932","volume":"119","author":"CS Beevers","year":"2006","unstructured":"Beevers CS, Li F, Liu L, Huang S (2006) Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119:757\u2013764","journal-title":"Int J Cancer"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","volume":"205","author":"A Dutton","year":"2005","unstructured":"Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG (2005) Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 205:498\u2013506","journal-title":"J Pathol"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/0008-5472.CAN-05-3018","volume":"66","author":"F Vega","year":"2006","unstructured":"Vega F, Medeiros LJ, Leventaki V et al (2006) Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66:6589\u20136597","journal-title":"Cancer Res"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S et al (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108:1668\u20131676","journal-title":"Blood"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","volume":"108","author":"S Uddin","year":"2006","unstructured":"Uddin S, Hussain AR, Siraj AK et al (2006) Role of phosphatidylinositol 3\u2032-kinase\/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178\u20134186","journal-title":"Blood"},{"key":"15_CR8","first-page":"1433","volume":"90","author":"S Hipp","year":"2005","unstructured":"Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T (2005) Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90:1433\u20131434","journal-title":"Haematologica"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","volume":"134","author":"K Wanner","year":"2006","unstructured":"Wanner K, Hipp S, Oelsner M et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475\u2013484","journal-title":"Br J Haematol"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1158\/0008-5472.CAN-04-4180","volume":"65","author":"P Wlodarski","year":"2005","unstructured":"Wlodarski P, Kasprzycka M, Liu X et al (2005) Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65:7800\u20137808","journal-title":"Cancer Res"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M et al (2006) Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165\u20135173","journal-title":"Clin Cancer Res"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12185-010-0707-5","volume":"92","author":"K Tobinai","year":"2010","unstructured":"Tobinai K, Ogura M, Maruyama D et al (2010) Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 92:563\u2013570","journal-title":"Int J Hematol"},{"key":"15_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP et al (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85:320\u2013324","journal-title":"Am J Hematol"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Reeder CB, LaPlant BR et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25:341\u2013347","journal-title":"Leukemia"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C, Zinzani PL, Gressin R et al (2012) A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97:1085\u20131091","journal-title":"Haematologica"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1008200307625","volume":"8","author":"S Ascani","year":"1997","unstructured":"Ascani S, Zinzani PL, Gherlinzoni F et al (1997) Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 8:583\u2013592","journal-title":"Ann Oncol"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 9:717\u2013720","journal-title":"Ann Oncol"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"KJ Savage","year":"2007","unstructured":"Savage KJ (2007) Peripheral T-cell lymphomas. Blood Rev 21:201\u2013216","journal-title":"Blood Rev"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316\u20132323","journal-title":"Blood"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ et al (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 48:3223\u20133231","journal-title":"Eur J Cancer"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1158\/0008-5472.CAN-06-0419","volume":"66","author":"HG Wendel","year":"2006","unstructured":"Wendel HG, Malina A, Zhao Z et al (2006) Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66:7639\u20137646","journal-title":"Cancer Res"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333\u2013339","journal-title":"Leukemia"},{"key":"15_CR24","first-page":"3801","volume":"28","author":"D Cejka","year":"2008","unstructured":"Cejka D, Preusser M, Fuereder T et al (2008) mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 28:3801\u20133808","journal-title":"Anticancer Res"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","volume":"113","author":"R Crazzolara","year":"2009","unstructured":"Crazzolara R, Cisterne A, Thien M et al (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113:3297\u20133306","journal-title":"Blood"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1756-9966-29-150","volume":"29","author":"L Gu","year":"2010","unstructured":"Gu L, Zhou C, Liu H et al (2010) Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res 29:150","journal-title":"J Exp Clin Cancer Res"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA 3rd et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588\u20131595","journal-title":"J Clin Oncol"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ijc.25742","volume":"129","author":"N Darwiche","year":"2011","unstructured":"Darwiche N, Sinjab A, Abou-Lteif G et al (2011) Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia\/lymphoma and apoptosis in peripheral T-cell lymphomas. Int J Cancer 129:993\u20131004","journal-title":"Int J Cancer"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10637-010-9558-4","volume":"30","author":"JJ Huang","year":"2012","unstructured":"Huang JJ, Li ZM, Huang Y et al (2012) Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Investig New Drugs 30:223\u2013235","journal-title":"Investig New Drugs"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402\u20133408","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0015-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-0015-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0015-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0015-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T01:52:20Z","timestamp":1715910740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0015-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,24]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0015-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,24]]},"assertion":[{"value":"11 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}